Aravive, Inc. Banner Image

Aravive, Inc. has reached its limit for free report views

Work for Aravive, Inc.? Upgrade Your Profile and unlock all your annual reports.

Aravive, Inc.

  • Ticker ARAV
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Aravive, Inc. Logo Image
  • 11-50 Employees
  • Based in Houston, Texas
Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive’s lead therapeutic, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth. Aravive recently successfully completed a Phase 1b trial of AVB-500 in platinumMore resistant ovarian cancer and selected 15 mg/kg as the dose for the next potential pivotal trial. Analysis of all safety data to date showed that AVB-500 has been generally well-tolerated with no dose-limiting toxicities or unexpected safety signals. While the Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mg/kg cohort experienced clinical benefit, with 1 complete response, 2 partial responses, and 2 stable disease. The Company also intends to initiate a Phase 1b/Phase 2 trial of AVB-500 in clear cell renal cell carcinoma later this year.
4.8 / 5.0 (112)

Aravive, Inc. reports have an aggregate usefulness score of 4.8 based on 112 reviews.

Aravive, Inc.

Most Recent Annual Report

Aravive, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Report Locked. Aravive, Inc. has reached its limit for free report views.

Older/Archived Annual Reports

Aravive, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!